Labrys Biologics Inc. announced key executive appointments to lead the development of RN-307, a Phase 2 ready anti-CGRP monoclonal antibody for the treatment of chronic migraine. Marcelo Bigal, M.D., Ph.D., joins the company as chief medical officer, along with Michael Chang, Ph.D., as vice president of project management; Michele Bronson, Ph.D., vice president of regulatory and quality; Rafael Escandón, Ph.D., MPH, as vice president of clinical operations; and Henry Stern as executive director of CMC. Dr. Bigal was the head of the Merck Investigator Study Program at Merck, Inc, and before that he was the global director for scientific affairs in neuropsychiatry at Merck, directly involved with Merck's migraine development programs. Prior to joining the comapny, Dr. Chang was vice president of R&D at Limerick BioPharma and vice president of project management at CV Therapeutics, where he was responsible for managing the company's key partnership to commercialize Ranexa(R) in Europe and led functions involving manufacturing, project management, lifecycle planning, and portfolio analysis. Prior to joining the company, Dr. Bronson was the vice president of regulatory, quality and project management at Medivation, Inc., where she was responsible for managing, prioritizing and selecting molecules to bring into development, and serving on joint oversight committees for collaborations. Dr. Escandón was most recently a consulting vice president of clinical outcome services at ICON, PLC where he built a team of specialized project managers, nurses and programmers for a novel electronic adjudication, surveillance and reporting system for clinical outcomes to sponsors and regulatory agencies. products. During Mr. Stern's tenure at Genentech, Mr. Stern was instrumental in gaining regulatory approval for the first multi-product biologics facilities and has been involved with multiple regulatory submissions and inspections.